combination therapies outperforming semaglutide Why You Might Tolerate One Weight Loss Drug Better Than Another

FDA Warns on Certain Forms of Compounded Semaglutide

22.15

★★★★☆4.8 (126)

Semaglutide did not associate with a higher proportion of SAEs among people initiating dialysis in CV or kidney outcomes trials. MACE and all-cause mortality event rates were numerically lower. #DCare #Article Read

24.49

★★★★★4.9 (98)

Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study - Vanek - 2024 - Diabetes, Obesity and Metabolism

24.69

★★★★★5.0 (157)

For patients undergoing kidney dialysis, the use of GLP-1 receptor agonist semaglutide showed safety, with no significant increase in serious cardiovascular adverse events or mortality. The findings were especially important in the

20.28

★★★★★4.7 (84)

Effects of Semaglutide on CKD in Patients With Type 2 Diabetes

26.85

★★★★★4.9 (203)

Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights

27.41

★★★★★5.0 (176)

Mechanistic effects of Semaglutide on kidney disease in type 2 diabetes: The REMODEL trial" by Katherine Tuttle et al, was awarded with ISNWCN Preserving Kidney Health: Top Scored Abstract. Visual abstract by

25.14

★★★★★4.8 (132)